RT Journal Article
SR Electronic
T1 A Scalable, Easy-to-Deploy, Protocol for Cas13-Based Detection of SARS-CoV-2 Genetic Material
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.04.20.052159
DO 10.1101/2020.04.20.052159
A1 Jennifer N. Rauch
A1 Eric Valois
A1 Sabrina C. Solley
A1 Friederike Braig
A1 Ryan S. Lach
A1 Morgane Audouard
A1 Jose Carlos Ponce-Rojas
A1 Michael S. Costello
A1 Naomi J. Baxter
A1 Kenneth S. Kosik
A1 Carolina Arias
A1 Diego Acosta-Alvear
A1 Maxwell Z. Wilson
YR 2020
UL http://biorxiv.org/content/early/2020/07/24/2020.04.20.052159.abstract
AB The COVID-19 pandemic has created massive demand for widespread, distributed tools for detecting SARS-CoV-2 genetic material. The hurdles to scalable testing include reagent and instrument accessibility, availability of highly-trained personnel, and large upfront investment. Here we showcase an orthogonal pipeline we call CREST (Cas13-based, Rugged, Equitable, Scalable Testing) that addresses some of these hurdles. Specifically, CREST pairs commonplace and reliable biochemical methods (PCR) with low-cost instrumentation, without sacrificing detection sensitivity. By taking advantage of simple fluorescence visualizers, CREST allows for a binary interpretation of results. CREST may provide a point- of-care solution to increase the distribution of COVID-19 surveillance.Competing Interest StatementThe authors have declared no competing interest.